These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 25089122)

  • 1. Changes in costs and effects after the implementation of disease management programs in the Netherlands: variability and determinants.
    Tsiachristas A; Cramm JM; Nieboer AP; Rutten-van Mölken MP
    Cost Eff Resour Alloc; 2014; 12():17. PubMed ID: 25089122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Disease Management Programs for Cardiovascular Risk and COPD in The Netherlands.
    Tsiachristas A; Burgers L; Rutten-van Mölken MP
    Value Health; 2015 Dec; 18(8):977-86. PubMed ID: 26686781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying and explaining the variability in development and implementation costs of disease management programs in the Netherlands.
    Tsiachristas A; Waters BH; Adams SA; Bal R; Mölken MP
    BMC Health Serv Res; 2014 Oct; 14():518. PubMed ID: 25343967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broader economic evaluation of disease management programs using multi-criteria decision analysis.
    Tsiachristas A; Cramm JM; Nieboer A; Rutten-van Mölken M
    Int J Technol Assess Health Care; 2013 Jul; 29(3):301-8. PubMed ID: 23759317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence.
    Ekpu VU; Brown AK
    Tob Use Insights; 2015; 8():1-35. PubMed ID: 26242225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct and indirect costs of COPD progression and its comorbidities in a structured disease management program: results from the LQ-DMP study.
    Kirsch F; Schramm A; Schwarzkopf L; Lutter JI; Szentes B; Huber M; Leidl R
    Respir Res; 2019 Oct; 20(1):215. PubMed ID: 31601216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a large scale implementation of disease management programmes in various Dutch regions: a study protocol.
    Lemmens KM; Rutten-Van Mölken MP; Cramm JM; Huijsman R; Bal RA; Nieboer AP
    BMC Health Serv Res; 2011 Jan; 11():6. PubMed ID: 21219620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [General practitioners' opinion and attitude towards DMPs and the change in practice routines to implement the DMP "diabetes mellitus type 2"].
    Miksch A; Trieschmann J; Ose D; Rölz A; Heiderhoff M; Szecsenyi J
    Z Evid Fortbild Qual Gesundhwes; 2011; 105(6):427-33. PubMed ID: 21843845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential for integrated care programmes to improve quality of care as assessed by patients with COPD: early results from a real-world implementation study in The Netherlands.
    Cramm JM; Rutten-Van Mölken MP; Nieboer AP
    Int J Integr Care; 2012; 12():e191. PubMed ID: 23593052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effectiveness of German disease management programs (DMPs) in patients with type 2 diabetes mellitus and coronary heart disease: results from an observational longitudinal study.
    Laxy M; Stark R; Meisinger C; Kirchberger I; Heier M; von Scheidt W; Holle R
    Diabetol Metab Syndr; 2015; 7():77. PubMed ID: 26388948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The increasing importance of a continence nurse specialist to improve outcomes and save costs of urinary incontinence care: an analysis of future policy scenarios.
    Franken MG; Corro Ramos I; Los J; Al MJ
    BMC Fam Pract; 2018 Feb; 19(1):31. PubMed ID: 29454331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Evaluations of Multicomponent Disease Management Programs with Markov Models: A Systematic Review.
    Kirsch F
    Value Health; 2016 Dec; 19(8):1039-1054. PubMed ID: 27987631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs and outcomes of the German disease management programme (DMP) for chronic obstructive pulmonary disease (COPD)-A large population-based cohort study.
    Achelrod D; Welte T; Schreyögg J; Stargardt T
    Health Policy; 2016 Sep; 120(9):1029-39. PubMed ID: 27552849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of physical activity in the management of COPD patients in the UK.
    Ramos M; Lamotte M; Gerlier L; Svangren P; Miquel-Cases A; Haughney J
    Int J Chron Obstruct Pulmon Dis; 2019; 14():227-239. PubMed ID: 30697043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Life prolonging of disease management programs in patients with type 2 diabetes is cost-effective.
    Drabik A; Büscher G; Sawicki PT; Thomas K; Graf C; Müller D; Stock S
    Diabetes Res Clin Pract; 2012 Feb; 95(2):194-200. PubMed ID: 22004943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simulation-based estimates of effectiveness and cost-effectiveness of smoking cessation in patients with chronic obstructive pulmonary disease.
    Atsou K; Chouaid C; Hejblum G
    PLoS One; 2011; 6(9):e24870. PubMed ID: 21949774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart failure disease management program: A review.
    AlHabeeb W
    Medicine (Baltimore); 2022 Aug; 101(31):e29805. PubMed ID: 35945723
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.